SCODiA Report by MLBI Lab

Single-Cell Atlas of Human Liver Cirrhosis Reveals Dysregulated Cellular Landscape, Intercellular Communication, and Therapeutic Targets

This study provides a high-resolution single-cell atlas of human liver cirrhosis, characterizing profound shifts in cell type populations, functional states, and intercellular communication networks compared to healthy controls. Key findings include a notable reduction in hepatocytes and innate lymphoid cells, coupled with an expansion of pro-inflammatory macrophages, activated hepatic stellate cells, and specific T cell subsets. Macrophages exhibit a pro-inflammatory M1-like polarization, while CD4+ T cells show increased activation and migratory potential, and cytotoxic T cells are diminished. Cell-cell interaction analysis highlights activated pro-fibrotic and inflammatory axes, particularly involving macrophages, hepatic stellate cells, and endothelial cells. Gene Ontology and GSEA reveal widespread metabolic reprogramming, inflammatory pathway activation, and ECM remodeling across diverse cell types. These integrated insights underscore the multifaceted pathogenesis of cirrhosis and identify several promising therapeutic targets.

Contents

  1. Dataset overview
  2. UMAP Visualization of Single-Cell Transcriptome Data in Liver Cirrhosis
  3. Major Cell Type Score Visualization on UMAP for Annotation Validation
  4. Marker Gene Expression Across Liver Cell Subsets
  5. Cell Type Population Shifts in Cirrhosis vs. Healthy Liver
  6. T Cell and Innate Lymphoid Cell Subpopulation Analysis in Cirrhosis
  7. T Cell Subset Population Shifts in Liver Cirrhosis
  8. Macrophage Subset Population Analysis in Cirrhosis
  9. Differential Abundance of Macrophage Subsets in Cirrhosis
  10. Cell-Cell Interaction Patterns in Healthy and Cirrhotic Liver
  11. Condition-Specific Cell-Cell Interaction Patterns in Cirrhotic Liver
  12. Cholangiocyte Condition-Specific Surfaceome Markers in Liver Cirrhosis
  13. Macrophage Condition-Specific Surfaceome Markers in Liver Cirrhosis
  14. Condition-Specific Surfaceome Markers in Hepatic Stellate Cells
  15. T cell CD4+ Condition-Specific Surfaceome Markers in Liver Cirrhosis
  16. Gene Ontology (GSA) Analysis for Hepatic Stellate Cells in Liver Cirrhosis
  17. Gene Set Enrichment Analysis (GSEA) of Cell-type Specific Pathways in Liver Cirrhosis
  18. Discussion
  19. Query List

0. Dataset overview

데이터셋 요약

사전 계산된 분석 결과

1. UMAP Visualization of Single-Cell Transcriptome Data in Liver Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP (Uniform Manifold Approximation and Projection) plots, a dimensionality reduction technique used to visualize high-dimensional single-cell RNA sequencing data in a 2D space. The purpose is to observe the overall structure of the dataset, evaluate the separation of cells based on different metadata categories (condition, sample, major cell type, minor cell type, and celltype_subset), and assess the quality of cell type annotations and potential batch effects. These visualizations provide a foundational understanding of the cellular landscape and how it changes across healthy and cirrhotic liver conditions.

Visual Summary

The UMAP plots display the relationships between 60,503 cells, colored according to different attributes:

Biological Interpretation

The UMAP visualizations provide critical insights into the cellular heterogeneity of the human liver in healthy and cirrhotic states.

  1. Disease-Associated Cellular Remodeling: The 'condition' UMAP clearly shows that while many cell populations are shared between healthy and cirrhotic livers, there are specific cell clusters that are predominantly or exclusively associated with cirrhosis. This indicates a significant cellular remodeling and activation of disease-specific cell states in cirrhosis. These unique clusters may represent immune cell infiltration, activation of specific stromal populations, or altered states of resident cells in response to chronic injury and fibrosis. For example, some peripheral clusters, rich in cirrhotic cells, might represent activated myofibroblasts (derived from hepatic stellate cells) or specific immune cell subsets involved in liver inflammation and fibrosis progression.
  2. Robust Cell Type Annotation: The clear separation of cell populations across all levels of cell type annotation (major, minor, subset) validates the quality and reliability of the cell type assignments. This robust clustering suggests that the gene expression profiles are distinct enough to differentiate between diverse cell types and their subtypes, forming a strong basis for downstream differential expression or pathway analyses. The presence of distinct subsets like different macrophage polarizations (M1, M2A, M2B, M2C, M2D) or T helper cell subsets (Th1, Th2, Th9, Th17, Th22, Tfh, Treg) underscores the biological complexity being captured.
  3. Minimal Batch Effects: The 'sample' UMAP indicates that cells from different samples are generally well-interspersed within the major clusters. This suggests that the primary biological variations (e.g., cell type identity, disease state) are more influential in shaping the UMAP embedding than technical variations between samples, which is crucial for reliable biological interpretation.
  4. Cellular Landscape of Cirrhosis: The data highlights the complexity of the liver microenvironment in cirrhosis. Specific cell subsets that appear enriched in the cirrhosis condition warrants further investigation. For instance, activated Hepatic stellate cells are key drivers of fibrosis in cirrhosis [Source: PubMed search for "hepatic stellate cell cirrhosis fibrosis": PubMed Search]. The observed distinct clusters in cirrhotic samples could represent these activated states or novel immune cell populations contributing to disease pathogenesis. The presence of various immune cell subsets (Myeloid, T cell, B cell, ILC, Mast cell) across both conditions, with potential enrichment or altered states in cirrhosis, points to the profound immune system involvement in chronic liver disease.

Annotation Notes

The UMAP plots demonstrate high-quality cell type annotation, with distinct clustering for most cell populations at major, minor, and subset levels. The clear separation observed provides confidence in the assigned cell identities. A small proportion of cells are labeled as 'unassigned' in the minor and subset UMAPs, indicating some cells did not definitively cluster with known populations. These 'unassigned' cells are sparsely distributed and do not form large, distinct clusters, suggesting they are either rare populations, transitional states, or cells with ambiguous transcriptional profiles. Overall, the consistent and well-separated clusters across different levels of annotation strongly support the biological validity of the cell type classifications.

2. Major Cell Type Score Visualization on UMAP for Annotation Validation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell type scores across the UMAP embedding, alongside the final celltype_major annotation. The purpose is to assess the robustness and consistency of the assigned major cell types by examining how well marker gene-derived scores for each cell type align with their respective annotated clusters in the dimensionality reduction space. This is a critical step for validating cell identity and the overall quality of the single-cell RNA-seq data annotation.

Visual Summary

The UMAP plots display the HICAT-derived major cell type scores, where higher scores (yellow/green) indicate stronger expression of marker genes characteristic of that cell type, and lower scores (purple) indicate weaker expression. The final plot shows the UMAP colored by the celltype_major annotation.

  1. Distinct Clustering: The overall UMAP embedding reveals well-separated clusters, suggesting a good resolution of distinct cell populations within the liver tissue.
  2. High Correspondence of Scores and Annotations:
  1. Specificity and Minimal Overlap: The scores are largely specific, with minimal "bleed-through" of high scores into clusters assigned to other major cell types. This indicates that the marker gene sets used for scoring are highly characteristic of their intended cell populations and that the clustering effectively segregates these cell types.

Biological Interpretation

The strong concordance between the HiCAT_major_score and the celltype_major annotations provides robust evidence for the accurate identification and demarcation of major cell populations within the human liver. This validation is particularly important in the context of disease such as cirrhosis, where changes in cell type composition or state can be critical.

Annotation Notes

This visualization serves as a crucial check for annotation quality. The observed strong agreement between cell type scores and assigned labels suggests that the celltype_major annotations are robust and reliable. This provides a high level of confidence for subsequent analyses built upon these cell type assignments. No significant misannotations or ambiguous cell type boundaries are apparent at the major cell type level based on these score distributions.

3. Marker Gene Expression Across Liver Cell Subsets

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of marker genes across various cell subsets identified in the AnnData object. The celltype_subset annotations are used as categories for cell groups on the y-axis, and selected marker genes are displayed on the x-axis. The purpose of this plot is to visually assess the specificity and expression levels of these markers, which in turn helps to validate or refine the existing cell type annotations. The user query specifically requested a marker expression dot plot for celltype_subset, with target_cell set to None, implying a broad marker discovery and visualization across all subsets. The plot is configured to highlight specific markers for each cell group, with var_group_rotation set to 45 degrees for readability of gene symbols.

Visual Summary

The dot plot visualizes gene expression characteristics for 37 distinct celltype_subset populations. Each row represents a cell subset, and each column represents a gene.

Biological Interpretation

This dot plot serves as a crucial identity-check for the celltype_subset annotations by examining the expression of known and putative marker genes. The overall pattern of discrete blocks of high expression (large, dark red dots) along the diagonal strongly supports the distinct identities of most annotated cell subsets within the human liver.

Here's a breakdown of key observations related to specific cell populations:

Liver Epithelial Cells:

Stromal Cells:

Myeloid Cells:

Lymphoid Cells:

The overall strong diagonal expression pattern with minimal off-target expression for the prominent markers indicates that the celltype_subset annotations are generally well-supported by these gene expression profiles.

Annotation Notes

The marker expression dot plot effectively validates the distinct identities of the majority of celltype_subset annotations. The presence of highly specific and highly expressed markers for most cell groups confirms that the clustering and annotation process has successfully segregated biologically meaningful populations.

In conclusion, the marker gene expression patterns overwhelmingly support the current celltype_subset annotations, indicating a high quality of cell type identification in this single-cell RNA-seq dataset from the human liver.

4. Cell Type Population Shifts in Cirrhosis vs. Healthy Liver

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot displaying the relative proportions of minor cell types within individual samples from human liver tissue. The samples are categorized into two conditions: 'cirrhosis' and 'healthy'. Each bar represents a single sample, with stacked segments showing the percentage contribution of different celltype_minor populations. The visualization helps to identify differences in cellular composition that may be associated with liver cirrhosis.

Visual Summary

The stacked bar plots illustrate the cellular heterogeneity across individual liver samples from both healthy and cirrhotic conditions.

Increase in Immune Cells in Cirrhosis:

Increase in Stromal/Biliary Cells in Cirrhosis:

Biological Interpretation

The observed shifts in cell type populations are highly consistent with the known pathology of liver cirrhosis.

Clinical or Translational Implications

The changes in cell type composition observed here provide valuable insights into the pathophysiology of cirrhosis and may have several clinical implications:

5. T Cell and Innate Lymphoid Cell Subpopulation Analysis in Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various T cell and Innate Lymphoid Cell (ILC) subsets across individual samples from both 'healthy' and 'cirrhosis' conditions. The data is derived from single-cell RNA sequencing of liver tissue, with samples grouped by disease state to highlight differences in immune cell composition at the 'celltype_subset' level.

Visual Summary

The stacked bar plots display the proportional distribution of T cell subsets and ILCs for each sample, separated into 'cirrhosis' and 'healthy' conditions. Each bar represents a single sample, with the height of colored segments indicating the percentage contribution of a specific cell type subset.

  1. Reduced Innate Lymphoid Cells (ILCs) and NK cells in Cirrhosis: A striking observation is the marked reduction, and in many samples near absence, of ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg, and NK cells in the 'cirrhosis' samples compared to 'healthy' samples. In healthy livers, these innate lymphocyte populations consistently contribute a noticeable proportion to the overall immune cell compartment, occupying the lower part of the stacked bars with darker red and orange hues.
  2. Dominance of T cell Subsets in Cirrhosis: In contrast to the healthy samples, the immune cell composition in cirrhotic livers is overwhelmingly dominated by various T cell subsets, particularly T cell (Cytotoxic), T cell (Naive), and T cell (Tfh). While these T cell subsets are also present in healthy samples, their relative proportion appears amplified in cirrhosis due to the substantial decrease in ILCs and NK cells.
  3. Consistency within Conditions: Within the 'cirrhosis' group, the pattern of reduced ILCs/NK cells and T cell dominance is largely consistent across all analyzed samples. Similarly, the presence of ILCs/NK cells is generally consistent across healthy samples, although there is some sample-to-sample variability in the exact proportions of each subset.
  4. T regulatory cells (Treg) and other T cell subsets: T cell (Treg) cells are present in both conditions, appearing as a thin dark blue segment towards the top of the bars. No dramatic proportional shifts are visually apparent for T cell (Treg) or other minor T helper (Th) cell subsets (Th1, Th17, Th2, Th22, Th9) based on this visualization, although their relative contributions are more discernible in healthy samples where the overall T cell compartment is less compressed by the lack of ILCs.

Biological Interpretation

The observed shift in immune cell populations, specifically the significant reduction of innate lymphoid cells (ILCs) and NK cells in cirrhotic livers compared to healthy ones, suggests profound changes in the liver's immune landscape during disease progression.

The reduced proportions of these innate immune cells in cirrhosis could indicate a compromised ability of the liver to mount effective early immune responses, clear senescent or damaged cells, or control chronic viral infections, potentially exacerbating liver damage and contributing to disease progression. This reduction could result from cell death, egress from the liver, or altered differentiation pathways under chronic inflammatory conditions.

Clinical or Translational Implications

The distinct immune cell composition in cirrhotic livers has several potential clinical implications:

---

References

  1. Sun, R., et al. (2015). Natural killer cells in liver injury and repair. *Journal of Autoimmunity*, 65, 52-61. PubMed Search: "NK cells liver cirrhosis"
  2. Trautwein, C., et al. (2020). Immune Cells in Liver Fibrosis. *Seminars in Liver Disease*, 40(2), 162-177. PubMed Search: "T cells liver fibrosis"
  3. Li, P., et al. (2021). The immune landscape of liver cirrhosis: mechanisms and therapeutic implications. *Frontiers in Immunology*, 12, 706225. PubMed Search: "immunotherapy cirrhosis"

6. T Cell Subset Population Shifts in Liver Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents box plots illustrating the proportions of various T cell subsets in liver tissue, comparing individuals with cirrhosis against healthy controls. The plots highlight statistically significant differences (p-value < 0.1) in the relative abundance of six specific T cell subsets: Regulatory T cells (Treg), T helper 17 cells (Th17), T helper 22 cells (Th22), Cytotoxic T cells (T_Cyto), Naive T cells (T_Naive), and T helper 1 cells (Th1).

Visual Summary

The visualization displays six individual box plots, each representing a different T cell subset, comparing its proportion (Y-axis) between 'cirrhosis' (blue boxes) and 'healthy' (orange boxes) conditions (X-axis). Each plot includes individual data points (black dots for actual values, open circles for outliers) to show the distribution of observations.

Key observations from the plots are:

Increased Proportions in Cirrhosis:

Decreased Proportions in Cirrhosis:

In summary, most of the T helper subsets (Treg, Th17, Th22, Th1) along with Naive T cells show increased proportions in cirrhosis, while Cytotoxic T cells are notably decreased.

Biological Interpretation

The observed shifts in T cell subset populations underscore a profound immune dysregulation within the liver microenvironment during cirrhosis.

  1. Elevated Pro-Inflammatory T Helper Cells (Th1, Th17, Th22): The significant increase in Th1, Th17, and Th22 cells in cirrhosis suggests a heightened inflammatory state.
  1. Increased Regulatory T cells (Treg): The significant expansion of Treg cells in cirrhotic livers could represent a compensatory mechanism by the immune system to suppress excessive inflammation and limit tissue damage. However, in chronic liver diseases, an increase in Tregs can sometimes be detrimental, potentially impairing anti-viral or anti-tumor immunity and contributing to immune tolerance or exhaustion in the context of unresolved chronic infection or hepatocellular carcinoma development. PubMed search: Treg cells cirrhosis liver
  2. Decreased Cytotoxic T cells (T_Cyto): The substantial reduction in Cytotoxic T cells is a critical finding. These cells are essential for eliminating virus-infected cells and tumor cells. Their diminished proportion in cirrhosis might indicate:
  1. Increased Naive T cells: An increase in Naive T cells in a chronically inflamed organ like a cirrhotic liver is somewhat unexpected, as chronic inflammation typically leads to their differentiation into effector or memory cells. This could suggest:

Collectively, these findings paint a picture of an imbalanced immune response in cirrhosis, characterized by an ongoing pro-inflammatory milieu alongside compromised cytotoxic immunity, potentially contributing to disease progression and complications.

Clinical or Translational Implications

The distinct shifts in T cell subset proportions observed in cirrhotic livers hold significant clinical and translational implications:

7. Macrophage Subset Population Analysis in Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of different macrophage subsets (Macrophage M1, M2A, M2B, M2C, M2D) within individual liver samples from both healthy individuals and patients with cirrhosis. The purpose is to identify potential shifts in macrophage polarization patterns associated with the progression of liver cirrhosis.

Visual Summary

The stacked bar plots display the proportional distribution of five macrophage subsets (M1, M2A, M2B, M2C, M2D) across various samples, segregated by 'cirrhosis' and 'healthy' conditions.

Biological Interpretation

Macrophages, including tissue-resident Kupffer cells and monocyte-derived macrophages, are crucial immune cells in the liver, demonstrating significant plasticity. Their polarization into distinct functional phenotypes, broadly categorized as M1 (pro-inflammatory) and M2 (anti-inflammatory, pro-resolving, pro-fibrotic), plays a pivotal role in liver homeostasis and disease pathogenesis.

https://pubmed.ncbi.nlm.nih.gov/?term=macrophage+polarization+cirrhosis

Clinical or Translational Implications

The distinct shift in macrophage subset populations observed in cirrhotic livers has important clinical and translational implications:

8. Differential Abundance of Macrophage Subsets in Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional representation of specific macrophage subsets, Macrophage (M1) and Macrophage (M2A), within the liver across two conditions: healthy and cirrhosis. The objective is to identify any statistically significant shifts in these cell populations that may contribute to the pathology of cirrhosis, a chronic liver disease characterized by inflammation and fibrosis. Box plots are employed to visualize the distribution of celltype proportions for each subset, and statistical testing identifies differences between conditions with a p-value cutoff of 0.1.

Visual Summary

The box plots display the celltype proportions for two macrophage subsets that exhibited statistically significant differences between healthy and cirrhotic liver samples:

Biological Interpretation

The observed shifts in macrophage subset proportions in cirrhosis are biologically significant, indicating a reprogramming of the immune microenvironment in the liver during disease progression.

In summary, the data indicates a dysregulation of macrophage polarization in cirrhosis, characterized by an increased proportion of pro-inflammatory M1-like macrophages and a decreased proportion of M2A-like macrophages, which normally contribute to tissue repair and immune regulation. This imbalance is a hallmark of chronic inflammatory diseases and plays a central role in the pathogenesis of liver cirrhosis.

Clinical or Translational Implications

The findings regarding macrophage subset dynamics in cirrhosis have several important clinical and translational implications:

9. Cell-Cell Interaction Patterns in Healthy and Cirrhotic Liver

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns in single-cell RNA-seq data from human liver tissue, comparing healthy individuals to those with cirrhosis. CellPhoneDB was used to identify potential ligand-receptor interactions between various cell types. The results are visualized as dot plots, where the size of each dot represents the statistical significance (-log10(p-value)) of the interaction, and the color intensity indicates the mean expression level (log2(mean)) of the interacting ligand-receptor pair. The analysis was configured to display up to 80 significant interactions per condition.

Visual Summary

The provided dot plots illustrate distinct cell-cell interaction landscapes in healthy and cirrhotic liver conditions.

CCI for Cirrhosis:

Key interactions highly prominent in cirrhosis include

CCI for Healthy:

Notable interactions in healthy liver include

Biological Interpretation

The differential cell-cell interaction patterns observed provide critical insights into the pathophysiology of liver cirrhosis. The dramatic increase and strengthening of specific ligand-receptor interactions in cirrhosis compared to healthy liver point towards active disease mechanisms:

  1. Extracellular Matrix Remodeling and Fibrogenesis: The most striking finding is the robust activation of SPP1-integrin and FN1-integrin signaling axes.
  1. Macrophage Activation and Immune Modulation:
  1. Angiogenesis and Vascular Remodeling: The activation of VEGFA-FLT1/KDR signaling, particularly among endothelial cells and between cholangiocytes and endothelial cells, indicates increased angiogenesis. Angiogenesis is a hallmark of chronic liver disease, contributing to pathological vascular changes and exacerbating portal hypertension.
  2. Apoptosis and Cell Homeostasis: The TNFSF10 (TRAIL)-TNFRSF10B (DR5) interaction could reflect ongoing cellular stress and programmed cell death in the cirrhotic liver, potentially impacting endothelial cell integrity or contributing to tissue injury.

In contrast, the healthy liver exhibits a more homeostatic pattern, with interactions like ANXA1-FPR1 and CCL5-CCR1 that are typically associated with basal immune surveillance and anti-inflammatory functions, rather than extensive tissue remodeling and inflammation.

Clinical or Translational Implications

The identified differential cell-cell interaction patterns offer several potential clinical and translational avenues for understanding and managing liver cirrhosis:

  1. Therapeutic Target Prioritization:
  1. Biomarker Discovery: Elevated levels of SPP1, soluble forms of integrins, or specific cytokines/chemokines associated with these prominent interaction pathways could serve as circulating or tissue-based biomarkers for disease activity, prognosis, or response to therapy in cirrhotic patients.
  2. Experimental Validation: These findings provide strong hypotheses for further experimental validation:

The clear distinction in CCI patterns between healthy and cirrhotic livers underscores the importance of these interactions in disease pathogenesis and highlights novel therapeutic opportunities for a condition with significant unmet medical need.

10. Condition-Specific Cell-Cell Interaction Patterns in Cirrhotic Liver

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis utilizes a dot plot to visualize cell-cell interaction (CCI) patterns between major immune and stromal cell types in liver samples, comparing cirrhotic conditions to healthy controls. The plot displays the scaled log strength of interactions (color intensity, red hues) and their statistical significance (-log10(p-value), dot size) across individual samples. The primary goal is to identify CCIs that are significantly different between cirrhotic and healthy states, highlighting those potentially driving disease pathology. The analysis focuses on interactions involving Myeloid cells (Macrophage, Dendritic cell), T cells, B cells, Stromal cells (Hepatic stellate cell, Fibroblast, Smooth muscle cell), Mast cells, and Endothelial cells.

Visual Summary

The dot plot clearly segregates cell-cell interaction patterns by condition. The upper section, corresponding to cirrhotic samples (highlighted by the blue box), shows a distinctly higher frequency and intensity of interactions compared to the healthy samples in the lower section.

The overall pattern strongly suggests a pro-inflammatory, pro-fibrotic, and immune-active microenvironment in cirrhotic livers, characterized by complex interplay between diverse immune and stromal cell populations.

Biological Interpretation

The observed condition-specific CCI patterns in cirrhosis reflect profound changes in the liver microenvironment, indicative of chronic inflammation, tissue remodeling, and immune dysregulation. Several key interaction pathways stand out:

  1. TYROBP-CD44 axis:
  1. CCL3/CCL5-CCR5 Chemokine Axis:
  1. CXCL12-CXCR4 Axis:
  1. Collagen-Integrin α1β1 Interactions:
  1. ANXA1-FPR1 Axis:
  1. HLA-E-NKG2A/KLRC1 Interactions:

Clinical or Translational Implications

The identified cell-cell interactions represent a rich landscape of potential therapeutic targets for liver cirrhosis:

11. Cholangiocyte Condition-Specific Surfaceome Markers in Liver Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of surfaceome markers in Cholangiocytes across various individual samples, categorized by their condition: "cirrhosis" or "healthy". The dataset comprises single-cell RNA-seq data from human liver tissue. The dot plot effectively visualizes two key aspects for each marker: the fraction of cells expressing the marker (indicated by dot size) and the mean expression level within those cells (indicated by color intensity, ranging from light red for low to dark red for high expression). The analysis aimed to identify condition-specific markers, with a focus on surfaceome proteins, which are particularly relevant for cell-cell interactions and potential therapeutic targeting.

Visual Summary

The dot plot clearly differentiates two major groups of markers based on their expression patterns: those highly expressed in cholangiocytes from cirrhotic samples and those predominantly expressed in healthy samples.

Overall, the plot reveals a distinct transcriptional shift in the surfaceome of cholangiocytes in the cirrhotic liver compared to healthy tissue, suggesting significant changes in cell identity, function, and interaction profiles during disease progression.

Biological Interpretation

The observed differential expression of surfaceome markers in cholangiocytes between healthy and cirrhotic livers points to profound changes in cellular processes, cell-cell communication, and interaction with the microenvironment in the context of cirrhosis.

Markers Upregulated in Cirrhotic Cholangiocytes

The markers highly expressed in cirrhotic cholangiocytes often relate to cellular stress, altered proliferation, inflammation, and remodeling of cell adhesion and signaling.

Markers Upregulated in Healthy Cholangiocytes

These markers are associated with normal cholangiocyte function and differentiation, and their downregulation in cirrhosis signifies a loss of healthy cellular identity and function.

Clinical or Translational Implications

The distinct expression profiles of surfaceome markers in cholangiocytes offer valuable insights for understanding cirrhosis pathogenesis and identifying potential therapeutic strategies.

Therapeutic Targets for Cholangiocyte-Driven Fibrosis and Dysfunction:

In conclusion, this analysis highlights several promising surfaceome markers in cholangiocytes that are differentially regulated in cirrhosis. These markers not only provide insights into the molecular mechanisms underlying liver fibrosis but also represent potential therapeutic targets for precision medicine approaches to manage and treat cirrhosis.

12. Macrophage Condition-Specific Surfaceome Markers in Liver Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome marker expression in Macrophages from liver tissue, comparing cirrhotic conditions to healthy controls using a dot plot. The goal is to highlight markers that are differentially expressed in macrophages between these two conditions, providing insights into disease mechanisms and potential therapeutic targets in cirrhosis. The plot displays the top distinguishing surfaceome markers found, primarily emphasizing those upregulated in cirrhosis.

Visual Summary

The dot plot visualizes the expression of 40 surfaceome markers across individual samples, grouped by condition (cirrhosis and healthy).

Biological Interpretation

The observed upregulation of numerous surfaceome markers in cirrhotic macrophages points towards their active and altered roles in the pathology of liver cirrhosis. These markers are involved in cell adhesion, immune signaling, tissue remodeling, and inflammatory responses, reflecting the complex environment of the cirrhotic liver. Here, we interpret a few prominent markers:

Clinical or Translational Implications

The identified surfaceome markers in cirrhotic macrophages represent potential targets for novel therapeutic interventions in liver cirrhosis.

13. Condition-Specific Surfaceome Markers in Hepatic Stellate Cells

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Hepatic stellate cells (HSCs) by comparing expression profiles between cirrhosis and healthy liver samples. The results are visualized using a dot plot, which displays the mean expression level (color intensity) and the fraction of cells expressing the marker (dot size) for each gene across different samples grouped by condition (cirrhosis vs. healthy). The primary goal is to identify surface proteins that are distinctly regulated in HSCs during cirrhosis, providing insights into disease mechanisms and potential therapeutic targets.

Visual Summary

The dot plot clearly illustrates distinct surfaceome expression patterns in Hepatic stellate cells between cirrhotic and healthy conditions.

Biological Interpretation

Hepatic stellate cells (HSCs) are central players in liver fibrosis and cirrhosis. In a healthy liver, HSCs are quiescent, storing vitamin A. Upon liver injury, they activate, proliferate, migrate, and differentiate into myofibroblast-like cells, becoming the primary producers of extracellular matrix (ECM) components, leading to fibrosis. The identified surfaceome markers provide insights into these activation processes and phenotypic changes.

Markers Upregulated in Cirrhosis

  1. ENG (Endoglin/CD105):

References

  1. THY1 (CD90):

References

  1. PDGFRA (Platelet-Derived Growth Factor Receptor Alpha):

References

  1. TGFBR2 (Transforming Growth Factor Beta Receptor 2):

References

  1. CD44:

References

  1. ITGA1 (Integrin Alpha 1):

References

  1. CD74 (MHC Class II Invariant Chain):

References

Markers Upregulated in Healthy Conditions

  1. CD9 (Tetraspanin 29):

References

  1. APP (Amyloid Beta Precursor Protein):

References

  1. AXL (AXL Receptor Tyrosine Kinase):

References

  1. NGFR (Nerve Growth Factor Receptor/p75NTR):

References

  1. SDC2 (Syndecan 2):

References

  1. CDH6 (Cadherin-6):

References

  1. JAG1 (Jagged Canonical Notch Ligand 1):

References

Clinical or Translational Implications

The identification of distinct surfaceome markers on Hepatic stellate cells in cirrhosis versus healthy liver has significant clinical and translational potential for the management of cirrhosis.

Therapeutic Targets for Cirrhosis

Biomarkers for Diagnosis and Prognosis

Monitoring Treatment Response

Understanding Disease Mechanisms

In summary, this analysis provides a rich set of surfaceome targets on Hepatic stellate cells that are highly relevant to the pathogenesis of cirrhosis. These findings are crucial for developing targeted interventions that specifically modulate HSC behavior to prevent or reverse liver fibrosis.

14. T cell CD4+ Condition-Specific Surfaceome Markers in Liver Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot visualizing the expression patterns of selected surfaceome markers in CD4+ T cells across individual samples from healthy and cirrhotic liver tissues. The markers were identified based on their differential expression between conditions, specifically focusing on surface-expressed proteins to highlight potential targets for therapeutic intervention or diagnostic utility. The aim is to discern how the surface phenotype of CD4+ T cells is altered in the context of liver cirrhosis, providing insights into their functional state and interactions within the diseased liver microenvironment.

Visual Summary

The dot plot effectively stratifies CD4+ T cell marker expression by condition (cirrhosis vs. healthy) and individual samples.

Key Observations:

  1. Cirrhosis-Associated Markers: A distinct cluster of markers, including IL2RG, LY6E, GYPC, SIT1, CD40LG, BST2, SIGIRR, LMAN2, and CXCR3, exhibits consistently high mean expression (dark red dots) and a large fraction of expressing cells (large dot size) across most cirrhotic samples. This indicates a prevalent and upregulated expression of these surface proteins on CD4+ T cells in liver cirrhosis. Notably, CD40LG and CXCR3 show particularly strong and widespread upregulation in the cirrhotic samples.
  2. Healthy-Associated Markers: Conversely, markers such as CCR7, SUSD3, and HLA-DRA show higher mean expression and larger dot sizes in several healthy samples compared to cirrhotic samples. This suggests these markers are more characteristic of CD4+ T cells in a healthy liver environment.
  3. Condition Specificity: The plot clearly delineates two major groups of markers: those prominently expressed in cirrhosis and those more associated with healthy tissue, highlighting condition-specific changes in CD4+ T cell surface phenotypes. The red boxes visually emphasize these distinct patterns.
  4. Sample Heterogeneity: While general trends are clear, there is some variability in expression levels and cell fractions even within the same condition, indicating potential individual differences or varying disease stages.

Biological Interpretation

The observed surfaceome marker profiles provide critical insights into the altered biology of CD4+ T cells in liver cirrhosis.

Markers Upregulated in Cirrhosis

The upregulation of these markers suggests an activated, inflammatory, and potentially migratory phenotype for CD4+ T cells in the cirrhotic liver:

Markers such as GYPC, SIT1, and LMAN2, while upregulated, have less clearly defined roles on the surface of CD4+ T cells in cirrhosis and warrant further investigation to elucidate their specific contributions.

Markers Upregulated in Healthy Conditions

The higher expression of these markers in healthy samples suggests roles in immune surveillance, homeostasis, or specific T cell subsets. Their relative downregulation in cirrhosis might indicate a shift from these states.

Clinical or Translational Implications

The identification of these cell-type-specific surfaceome markers provides valuable insights for understanding the pathogenesis of cirrhosis and developing targeted therapies.

  1. Therapeutic Targets for Cirrhosis:
  1. Biomarkers: The identified condition-specific markers could serve as diagnostic or prognostic biomarkers for cirrhosis, particularly if they can be detected via non-invasive means (e.g., flow cytometry of peripheral blood T cells if correlating with liver-resident cells) or in liver biopsies to assess disease severity or progression.
  2. Validation and Functional Studies: Further experimental validation is crucial. This would involve:

In conclusion, the surfaceome markers identified in this analysis, particularly CD40LG and CXCR3, provide compelling evidence for altered CD4+ T cell function in cirrhosis and present promising avenues for the development of targeted therapies to mitigate liver inflammation and fibrosis.

15. Gene Ontology (GSA) Analysis for Hepatic Stellate Cells in Liver Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results for Hepatic stellate cells (HSCs), a key cell type in the liver, comparing two conditions: "cirrhosis vs others" and "healthy vs others". The "others" in this context refers to the complementary condition present in the dataset (i.e., healthy samples for the cirrhosis comparison, and cirrhotic samples for the healthy comparison). The results are visualized as bar plots, displaying the top enriched GO terms sorted by their statistical significance (-log(p-value) and -log(q-value)), indicating pathways that are significantly upregulated in HSCs within each respective condition.

Visual Summary

Hepatic Stellate Cells in Cirrhosis

The bar plot for Hepatic stellate cells in the cirrhosis condition reveals a strong enrichment of pathways associated with extracellular matrix (ECM) remodeling, cellular adhesion, and inflammatory processes.

Hepatic Stellate Cells in Healthy Liver

The bar plot for Hepatic stellate cells in the healthy condition highlights pathways primarily related to fundamental cellular machinery and regulatory processes.

Biological Interpretation

The Gene Ontology analysis effectively distinguishes the biological states of Hepatic stellate cells in healthy versus cirrhotic livers.

In cirrhosis, HSCs undergo activation, transitioning from a quiescent, vitamin A-storing phenotype to a myofibroblast-like cell that is highly proliferative and fibrogenic. The enriched pathways directly reflect this activation:

In contrast, healthy Hepatic stellate cells show enrichment for fundamental cellular processes, consistent with their quiescent state:

The comparative analysis clearly indicates a shift in HSC biology during cirrhosis, moving from a metabolically balanced, quiescent state to a highly active, matrix-producing, and inflammation-responsive phenotype.

Clinical or Translational Implications

The identified pathways in Hepatic stellate cells during cirrhosis offer potential targets for therapeutic intervention in liver fibrosis and cirrhosis:

These findings underscore the importance of Hepatic stellate cells as central players in cirrhosis pathogenesis and highlight specific biological processes that could be leveraged for developing targeted anti-fibrotic therapies.

16. Gene Set Enrichment Analysis (GSEA) of Cell-type Specific Pathways in Liver Cirrhosis

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results across various liver cell types (celltype_minor) in the context of cirrhosis. The dot plot visualizes pathways that are significantly enriched or depleted in cells from cirrhotic livers compared to healthy controls, as well as the inverse comparison (healthy versus cirrhotic cells). The objective is to identify cell-type specific biological processes and molecular pathways dysregulated in cirrhosis.

Visual Summary

The dot plot displays the GSEA results for 120 gene sets (pathways) across 12 distinct cell types, each compared between "cirrhosis vs. others" (referring to healthy controls for that cell type) and "healthy vs. others" (referring to cirrhotic samples for that cell type).

Overall, the plot reveals widespread and cell-type specific alterations in pathway activity in cirrhotic livers, with clear patterns of both pathway upregulation (red) and downregulation (blue). Highly significant (large dots) and strongly enriched/depleted (bright red/blue) pathways are evident across multiple cell types.

Biological Interpretation

The GSEA results highlight several key biological themes characteristic of liver cirrhosis, demonstrating significant shifts in immune responses, metabolic functions, and fibrotic processes across various liver cell populations.

1. Robust Inflammatory and Immune Activation in Myeloid and Lymphoid Cells

Chemokine signaling pathway

NF-kappa B signaling pathway

These findings underscore the chronic inflammatory state and persistent immune cell activation driving cirrhosis progression.

2. Metabolic Reprogramming and Impaired Liver Function

Fatty acid degradation and Fatty acid elongation

Cholesterol metabolism

Peroxisome

These patterns indicate a significant metabolic shift and dysfunction in cirrhotic liver cells, moving away from oxidative and lipid metabolism, which contributes to disease pathology.

3. Fibrosis and Extracellular Matrix Remodeling

ECM-receptor interaction

Focal adhesion

These findings confirm the central role of these cell types in producing and remodeling the extracellular matrix, a hallmark of liver fibrosis.

4. Cell Stress, Apoptosis, and Proliferation

5. Cell-type Specificity and Consistency

While some pathways (e.g., inflammatory, metabolic) show broad dysregulation across multiple cell types, others are highly cell-type specific. For instance, "Phagosome" is predominantly enriched in Macrophages, while "T cell receptor signaling pathway" is specific to T cells. The inverse correlation between "cirrhosis_vs_others" and "healthy_vs_others" columns consistently validates these observed trends.

Clinical or Translational Implications

The comprehensive GSEA results provide valuable insights into the underlying molecular mechanisms of liver cirrhosis with potential clinical and translational implications:

17. Discussion

The single-cell RNA sequencing analysis of human liver tissue provides a high-resolution view of the cellular and molecular changes underpinning cirrhosis. A central finding is the extensive cellular remodeling, marked by a substantial reduction in healthy hepatocytes and innate lymphoid cells (ILCs, NK cells), alongside a notable expansion of pro-fibrotic (activated Hepatic stellate cells, Fibroblasts, Cholangiocytes) and inflammatory immune cell populations (Macrophages, T cells) in cirrhotic livers (Section 4, 5). This cellular shift is not merely quantitative but reflects a qualitative change in cell states, as evidenced by cell-type specific marker expression and pathway dysregulation (Section 3, 11-14, 16).

Immune dysregulation is a prominent feature of cirrhosis. Macrophages, a major myeloid population, exhibit a distinct shift towards a pro-inflammatory M1 phenotype, with a significant increase in M1 cells and a decrease in potentially reparative M2A cells (Section 7, 8). This M1 dominance fuels a persistent inflammatory environment, characterized by upregulated inflammatory signaling pathways (e.g., NF-κB, chemokine signaling, IL-17) across myeloid and lymphoid cells (Section 16). T cell populations also undergo significant rebalancing (Section 6): while cytotoxic T cells are notably decreased, regulatory T cells (Tregs) and pro-inflammatory T helper subsets (Th1, Th17, Th22) are significantly increased. This composite T cell profile suggests an impaired ability to clear damaged cells or pathogens alongside an exaggerated inflammatory response, potentially contributing to immune exhaustion and disease progression. CD4+ T cells in cirrhosis show upregulation of activation and migratory markers like CD40LG and CXCR3 (Section 14), further supporting their pathogenic role.

Fibrogenesis and extracellular matrix (ECM) remodeling are inextricably linked to the activation of Hepatic stellate cells (HSCs) and Cholangiocytes, which transform into myofibroblast-like cells and undergo pathological proliferation (ductular reaction), respectively. Our data strongly supports this, showing HSCs in cirrhosis are enriched for pathways of ECM-receptor interaction, focal adhesion, and PI3K-Akt signaling (Section 15). Furthermore, HSCs in cirrhosis upregulate key surface markers like ENG (CD105), THY1 (CD90), PDGFRA, and TGFBR2, which are well-established drivers of fibrogenesis and cellular activation (Section 13). Cholangiocytes similarly show upregulation of markers related to proliferation (ERBB3, EFNA1), inflammation (HLA-DRB1), and altered adhesion (TSPANs, EMP2, PLXNB2) (Section 11), indicating their active contribution to disease. Conversely, healthy HSCs and Cholangiocytes express markers associated with quiescence and normal function (e.g., NGFR, CD9, SCTR), which are downregulated in cirrhosis.

Cell-cell interaction analysis reveals a profoundly altered communication network in cirrhotic livers (Section 9, 10). Macrophages emerge as central orchestrators, showing strong interactions with T cells, endothelial cells, and cholangiocytes. Highly prominent axes in cirrhosis include SPP1-integrin and FN1-integrin, indicating robust ECM remodeling and inflammatory signaling. APP-TREM2 interactions suggest specific macrophage activation. Chemokine (CCL3/CCL5-CCR5, CXCL12-CXCR4) and collagen-integrin α1β1 interactions are significantly upregulated, driving immune cell recruitment and sustained fibrogenesis. Angiogenesis is also suggested by VEGFA-FLT1/KDR signaling, particularly among endothelial cells. These interactions highlight the complex interplay between immune, stromal, and epithelial cells that fuels disease progression.

Metabolic reprogramming is a pervasive feature, with GSEA revealing a widespread downregulation of oxidative phosphorylation, fatty acid metabolism, and xenobiotic metabolism across multiple cell types in cirrhosis (Section 16). This indicates significant cellular stress and functional impairment, contributing to the overall decompensation of the cirrhotic liver.

In summary, this single-cell atlas provides a detailed molecular and cellular roadmap of human liver cirrhosis, revealing a dynamic interplay of inflammation, fibrosis, and metabolic dysregulation orchestrated by diverse cell types. The identified cell-type-specific pathological markers and activated intercellular communication pathways offer compelling evidence for the development of targeted therapeutic strategies.

Hypotheses:

  1. The sustained pro-inflammatory (M1-like) polarization of macrophages, characterized by increased expression of BSG, AXL, VCAM1, and IL13RA1, drives chronic inflammation and activates hepatic stellate cells, thereby accelerating liver fibrosis in cirrhosis.
  2. The combination of decreased cytotoxic T cells (T_Cyto) and increased regulatory (Treg) and pro-inflammatory (Th1, Th17, Th22) T cell subsets, alongside enhanced CD4+ T cell activation (CD40LG, CXCR3), collectively compromises anti-viral/anti-tumor immunity while perpetuating pathogenic inflammation and fibrogenesis.
  3. Activated Hepatic Stellate Cells (HSCs) in cirrhosis, characterized by upregulation of ENG, THY1, PDGFRA, and TGFBR2, interact with immune cells and the altered ECM via specific integrins and chemokine axes (e.g., collagen-integrin α1β1, CXCL12-CXCR4), forming a self-sustaining pro-fibrotic loop.
  4. Cholangiocytes in cirrhosis undergo pathological proliferation (ductular reaction) and acquire an inflammatory/migratory phenotype (upregulating ERBB3, EFNA1, HLA-DRB1), contributing to chronic inflammation and fibrosis, partly driven by altered gap junction communication (GJB1).
  5. Widespread downregulation of oxidative phosphorylation and fatty acid metabolism across multiple liver cell types contributes to cellular stress, impairs liver regeneration, and exacerbates inflammation and fibrogenesis in cirrhosis.

Potential therapeutic targets:

  1. SPP1-Integrin Axis (Macrophages, T cells, Endothelial cells, Cholangiocytes): SPP1 is a key driver of liver fibrosis, promoting cell adhesion, migration, survival, and immune modulation. Its robust activation with multiple integrins indicates a central role in perpetuating inflammation and fibrotic scar formation. Evidence: High significance and expression in CCI for cirrhosis (Section 9, 10); GeneCards and PubMed literature confirm its role in liver fibrosis. Validation: Block SPP1 production or integrin binding using antibodies or small molecule inhibitors in primary human liver cell co-cultures and preclinical models of liver fibrosis (e.g., CCl4, NASH models). Assess fibrosis markers, inflammation, and cellular activation.
  2. CCR5 (Macrophages, T cells, Endothelial cells): Part of the CCL3/CCL5-CCR5 chemokine axis, crucial for recruiting and activating various immune cells to inflammatory sites, driving chronic liver inflammation and fibrogenesis. Evidence: Elevated CCL3/CCL5-CCR5 interactions in cirrhosis (Section 10). Validation: Test the CCR5 inhibitor maraviroc (FDA-approved for HIV) in preclinical models of liver fibrosis to confirm reduction in immune cell infiltration, inflammation, and fibrogenic responses.
  3. CXCR4 (Hepatic stellate cells, Endothelial cells, Macrophages): The CXCL12-CXCR4 axis is highly active in cirrhosis, promoting HSC migration, proliferation, fibrogenic differentiation, immune cell recruitment, and neovascularization. Evidence: Strong CXCL12-CXCR4 interactions involving HSCs and other cell types in cirrhosis (Section 10). Validation: Evaluate CXCR4 antagonists (e.g., plerixafor) in liver fibrosis models to assess reduction in HSC activation, immune cell infiltration, and fibrosis burden.
  4. ERBB3 (Cholangiocytes): Upregulation in cirrhotic cholangiocytes points to enhanced proliferative and survival signaling, driving pathological cholangiocyte proliferation (ductular reaction) and subsequent fibrosis. Evidence: Significantly upregulated in cirrhotic cholangiocytes (Section 11); ERBB3 activation is implicated in promoting cell proliferation and survival in many cancers and fibrotic conditions. Validation: Test ERBB3 inhibitors (e.g., patritumab, small molecule kinase inhibitors) in cholangiocyte organoids or liver fibrosis models to reduce cholangiocyte proliferation and fibrosis.
  5. SCTR (Secretin Receptor) (Cholangiocytes): Significant downregulation in cirrhotic cholangiocytes indicates impaired normal bile duct physiology, contributing to cholestasis and liver injury. Restoring its function could improve bile flow. Evidence: Dramatically downregulated in cirrhotic cholangiocytes (Section 11); SCTR is crucial for normal cholangiocyte function (bicarbonate and fluid secretion). Validation: Administer secretin analogs or SCTR agonists in preclinical models of cholestatic liver disease or cirrhosis to assess improved bile flow, reduced liver injury, and potential support for cholangiocyte regeneration.
  6. AXL (Macrophages): Upregulated in cirrhotic macrophages, AXL signaling promotes pro-fibrotic activation, efferocytosis of damaged cells, and survival of HSCs, exacerbating fibrosis and inflammation. Evidence: Highly expressed in cirrhotic macrophages (Section 12); GeneCards and PubMed literature support its role in fibrosis. Validation: Test AXL inhibitors (in clinical trials for oncology) in liver fibrosis models to modulate macrophage activation, reduce HSC survival, and dampen fibrosis.
  7. VCAM1 (Macrophages): Upregulated on cirrhotic macrophages, VCAM1 enhances recruitment of immune cells into inflamed liver tissue, contributing to sustained inflammation and progressive fibrosis. Evidence: Substantial upregulation in cirrhotic macrophages (Section 12); VCAM1 is crucial for leukocyte trafficking. Validation: Block VCAM1-mediated interactions using anti-VCAM1 antibodies or antagonists of its ligand (VLA-4) in liver fibrosis models to assess reduction in inflammatory cell infiltration and fibrosis progression.
  8. ENG (Endoglin/CD105) (Hepatic stellate cells): A coreceptor for TGF-β, crucial for its pro-fibrogenic signaling. Its upregulation on activated HSCs promotes fibrogenesis and vascular remodeling. Evidence: Highly upregulated on cirrhotic HSCs (Section 13); well-established marker for fibrosis and a key component of TGF-β signaling. Validation: Use ENG-blocking antibodies or inhibitors of TGF-β signaling in liver fibrosis models to attenuate HSC activation, ECM deposition, and vascular changes.
  9. PDGFRA (Platelet-Derived Growth Factor Receptor Alpha) (Hepatic stellate cells): A receptor tyrosine kinase driving HSC proliferation and migration, key processes in fibrogenesis. Evidence: High PDGFRA expression on activated HSCs in cirrhosis (Section 13); PDGF is a potent mitogen and chemoattractant for HSCs. Validation: Repurpose PDGFRA inhibitors (e.g., imatinib, nintedanib) from other fibrotic diseases for liver fibrosis models to reduce HSC proliferation and fibrogenesis.
  10. CD40LG (CD40 Ligand / CD154) (CD4+ T cells): A critical co-stimulatory molecule on activated T cells, promoting chronic inflammation, B cell activation, and fibrogenesis via the CD40-CD40LG axis. Evidence: Consistently high expression on CD4+ T cells in cirrhotic samples (Section 14); pivotal in chronic inflammation and fibrogenesis. Validation: Investigate anti-CD40LG antibodies (explored in autoimmune conditions) in liver fibrosis models to dampen T cell-mediated immune activation, B cell responses, and fibrogenic pathways.

Follow-up validation ideas:

  1. Isolate primary human liver macrophages from cirrhotic and healthy samples, culture them, and treat with inhibitors targeting BSG, AXL, VCAM1, or IL13RA1. Measure M1/M2 markers, pro-fibrotic cytokine secretion (e.g., TGF-β, TNF-α), and their effect on co-cultured HSC activation/collagen production.
  2. Utilize liver fibrosis mouse models (e.g., CCl4-induced, NASH models). Administer antibodies blocking CD40LG or CXCR3, or adoptive transfer of specific T cell subsets. Assess liver fibrosis markers, inflammation, and T cell composition/function by flow cytometry or scRNA-seq.
  3. Employ in vitro and in vivo models to test inhibitors of ENG, PDGFRA, or TGFBR2, or agents disrupting collagen-integrin α1β1 interactions (e.g., integrin blocking antibodies). Measure HSC proliferation, activation markers (alpha-SMA), and collagen deposition.
  4. Establish primary human cirrhotic cholangiocyte cultures or use 3D organoid models. Test ERBB3 or EFNA1 inhibitors for their effect on cholangiocyte proliferation, migration, and secretion of pro-fibrotic factors. Investigate the impact of SCTR agonists on bile secretion and differentiation.
  5. Use animal models of cirrhosis to assess the impact of metabolic modulators (e.g., fatty acid oxidation enhancers, mitochondrial function improvers) on liver pathology, inflammation, and fibrosis progression.

Limitations:

The current study, based on single-cell RNA sequencing data, has several limitations. Firstly, single-cell dissociation can induce stress responses or alter cell proportions, potentially affecting the observed transcriptomic profiles and cell counts. Secondly, scRNA-seq inherently provides a static snapshot of the disease, and longitudinal studies would be needed to understand the dynamic progression of cellular changes in cirrhosis. While cell-cell interaction inference provides valuable hypotheses, it is computationally derived and requires experimental validation (e.g., using spatial transcriptomics or functional co-culture assays) to confirm direct physical interactions and their functional consequences. The dataset's focus on 'cirrhosis' and 'healthy' conditions provides a strong comparison, but future studies could benefit from including intermediate stages of liver fibrosis to capture a more complete disease spectrum. Finally, while human samples offer direct clinical relevance, the lack of immediate functional validation for many of the identified targets means that their therapeutic potential remains hypothetical and requires extensive preclinical and clinical development.

18. Query List

  1. Show and save UMAPs for condition, sample, major cell type, minor cell type, and celltype_subset in two columns.
  2. Show major cell type scores on UMAP and save the result.
  3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
  4. Show and save a population bar plot of minor cell types.
  5. Show and save a population bar plot of T cell subsets.
  6. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  7. Show and save a population bar plot of macrophage subsets.
  8. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  9. Show and save cell-cell interaction patterns. Select at most 80 cell-cell interactions per group.
  10. Find cell-cell interactions involving major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms and, where relevant, its potential as a therapeutic target and related therapeutic agents.
  11. Show marker expressions for Cholangiocyte in a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Cirrhosis and related therapeutic agents.
  12. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Cirrhosis and related therapeutic agents.
  13. Show marker expressions for Hepatic stellate cell in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Cirrhosis and related therapeutic agents.
  14. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Cirrhosis and related therapeutic agents.
  15. Show Gene Ontology (GSA) analysis results for Hepatic stellate cell as a bar plot, and save the result.
  16. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.
↑ Top